

corrected to read “Division of Facilities and Property Management (DCIBBB).”

3. On page 58807, in the second column, “Laboratory Support Branch (DCIBBBB1)” is corrected to read “Laboratory Support Branch (DCIBBB1).”

4. On page 58807, in the third column, “Medical Products Travel Branch (DCIBBD2)” is corrected to read “Medical Products Foreign Travel Branch (DCIBBD2).”

5. On page 58807, in the third column, “Human and Animal Food Travel Branch (DCIBBD3)” is corrected to read “Human and Animal Food Foreign Travel Branch (DCIBBD3).”

6. On page 58808, in the first column, “Project Management Branch 1 (DCIDB1)” is corrected to read “Project Management Branch 1 (DCIDB2).”

7. On page 58808, in the first column, “Project Management Branch 2 (DCIDB2)” is corrected to read “Project Management Branch 2 (DCIDB3).”

8. On page 58808, in the first column, “Foreign Human and Animal Food Inspections Branch 1 (DCIEBA)” is corrected to read “Foreign Human and Animal Food Inspections Branch 1 (DCIEBA1).”

9. On page 58808, in the second column, “Human and Animal Food Investigations Branch 2 (DCIECF2)” is corrected to read “Human and Animal Food Compliance Branch (DCIECF2).”

10. On page 58808, in the second column, “Human and Animal Food Compliance Branch (DCIECF3)” is corrected to read “Human and Animal Food Investigations Branch 2 (DCIECF3).”

11. On page 58808, in the third column, “Chemistry Branch (DCIFCD1)” is corrected to read “Chemistry Branch (DCIFCD2).”

12. On page 58808, in the third column, “Microbiological Sciences Branch (DCIFCD2)” is corrected to read “Microbiological Sciences Branch (DCIFCD3).”

13. On page 58809, in the first column, “Bioresearch Monitoring Operations Staff (DCIGA1)” is corrected to read “Operations Staff (DCIGA1).”

14. On page 58809, in the first column, “Operations Staff (DCIGA2)” is corrected to read “Bioresearch Monitoring Dedicated Foreign Cadre Staff (DCIGA2).”

15. On page 58809, in the first column, “Bioresearch Monitoring Dedicated Foreign Cadre Staff (DCIGA3)” is removed.

16. On page 58809, in the second column, “Division of Information Disclosure Policy (DCIHBD)” is corrected to read “Division of Information Disclosure (DCIHBD).”

17. On page 58809, in the third column, “Disclosure Policy Branch (DCIHBD3)” is corrected to read “Disclosure Branch (DCIHBD3).”

18. On page 58809, in the third column, “Produce Branch (DCIHBD4)” is corrected to read “Produce Branch (DCIHA3).”

19. On page 58809, in the third column, “Imports Policy Branch (DCIHEA3)” and “Division of Planning and Evaluation (DCIHEB)” are removed.

20. On page 58809, in the third column, “Division of Enforcement (DCIHEC)” is corrected to read “Division of Compliance and Enforcement (DCIHEC).”

21. On page 58809, in the third column, “Recall Operations Branch (DCIHEC1)” is corrected to read “Recalls Branch (DCIHEC1).”

22. On page 58809, in the third column, “Northern Boarder Import Investigations Branch I (DCIIH1)” is corrected to read “Northern Border Import Investigations Branch I (DCIIH1).”

23. On page 58809, in the third column, “Northern Boarder Import Investigations Branch II (DCIIH2)” is corrected to read “Northern Border Import Investigations Branch II (DCIIH2).”

24. On page 58809, in the third column, “Northern Boarder Import Compliance Branch (DCIIH3)” is corrected to read “Northern Border Import Compliance Branch (DCIIH3).”

25. On page 58809, in the third column, “Office of Information Systems Management (DCIJ)” is corrected to read “Office of Information Systems Management (DCIK).”

26. On page 58809, in the third column, “Division of Enforcement Systems Solutions (DCIJA)” is corrected to read “Division of Enforcement Systems Solutions (DCIKA).”

27. On page 58809, in the third column, “Enforcement Systems Branch (DCIJA1)” is corrected to read “Enforcement Systems Branch (DCIKA1).”

28. On page 58810, in the first column, “Enforcement Data Management Branch (DCIJA2)” is corrected to read “Enforcement Data Management Branch (DCIKA2).”

29. On page 58810, in the first column, “Division of Import Systems Solutions (DCIJB)” is corrected to read “Division of Import Systems Solutions (DCIKB).”

30. On page 58810, in the first column, “Import Systems Branch (DCIJB1)” is corrected to read “Import Systems Branch (DCIKB1).”

31. On page 58810, in the first column, “Import Data Management

Branch (DCIJB2)” is corrected to read “Import Data Management Branch (DCIKB2).”

32. On page 58810, in the first column, “Division of Information Technology Planning and Management Services (DCIJC)” is corrected to read “Division of Information Technology Planning and Management Services (DCIKC).”

33. On page 58810, in the first column, “Solutions Planning Branch (DCIJC1)” is corrected to read “Solutions Planning Branch (DCIKC1).”

34. On page 58810, in the first column, “Information Technology Management and Governance Services Branch (DCIJC2)” is corrected to read “Information Technology Management and Governance Services Branch (DCIKC2).”

**Elizabeth J. Gramling,**

*Executive Secretary to the Department,  
Department of Health and Human Services.*

[FR Doc. 2022–25409 Filed 11–21–22; 8:45 am]

**BILLING CODE P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. FDA–2022–N–2841]

### Science Board to the Food and Drug Administration Advisory Committee; Notice of Meeting

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA or Agency) announces a forthcoming public advisory committee meeting of the Science Board to the Food and Drug Administration (Science Board). The Science Board provides advice to the Commissioner of Food and Drugs and other appropriate officials on specific, complex scientific and technical issues important to FDA and its mission, including emerging issues within the scientific community. Additionally, the Science Board provides advice to the Agency on keeping pace with technical and scientific developments, including in regulatory science, input into the Agency’s research agenda, and on upgrading its scientific and research facilities and training opportunities. It will also provide, where requested, expert review of Agency-sponsored intramural and extramural scientific research programs. The meeting will be open to the public.

**DATES:** The meeting will be held virtually on December 8, 2022, from 9 a.m. to 4 p.m. Eastern Time.

**ADDRESSES:** Please note that due to the impact of this COVID-19 pandemic, all meeting participants will be joining this advisory committee meeting via an online teleconferencing platform. Answers to commonly asked questions about FDA advisory committee meetings may be accessed at: <https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm408555.htm>.

**FOR FURTHER INFORMATION CONTACT:**

Rakesh Raghuvanshi, Office of the Chief Scientist, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 1, Rm. 3309, Silver Spring, MD 20993, 301-796-4769, [rakesh.raghuvanshi@fda.hhs.gov](mailto:rakesh.raghuvanshi@fda.hhs.gov), or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area). A notice in the **Federal Register** about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the Agency's website at <https://www.fda.gov/AdvisoryCommittees/default.htm> and scroll down to the appropriate advisory committee meeting link, or call the advisory committee information line to learn about possible modifications before coming to the meeting.

**SUPPLEMENTARY INFORMATION:**

**Agenda:** The meeting presentations will be heard, viewed, captioned, and recorded through an online teleconferencing platform. The Science Board will consider research needs for the evaluation of potential adverse health effects in children associated with oral cadmium exposure. The Science Board will also hear about the Agency's cross-cutting regulatory science research activities and its recent Focus Areas of Regulatory Science report.

FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its website prior to the meeting, the background material will be made publicly available on FDA's website at the time of the advisory committee meeting. Background material and the link to the online teleconference meeting room will be available at <https://www.fda.gov/AdvisoryCommittees/Calendar/default.htm>. Scroll down to the appropriate advisory committee meeting link. The meeting will include slide

presentations with audio components to allow the presentation of materials in a manner that most closely resembles an in-person advisory committee meeting.

**Procedure:** Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person on or before December 2, 2022. Oral presentations from the public will be scheduled between approximately 11 a.m. and 12 p.m. Those individuals interested in making formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before December 1, 2022. Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by December 2, 2022.

For press inquiries, please contact the Office of Media Affairs at [fdaoma@fda.hhs.gov](mailto:fdaoma@fda.hhs.gov) or 301-796-4540.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with disabilities. If you require accommodations due to a disability, please contact Rakesh Raghuvanshi (see **FOR FURTHER INFORMATION CONTACT**) at least 7 days in advance of the meeting.

FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our website at <https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm> for procedures on public conduct during advisory committee meetings.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: November 16, 2022.

**Lauren K. Roth,**

*Associate Commissioner for Policy.*

[FR Doc. 2022-25405 Filed 11-21-22; 8:45 am]

**BILLING CODE 4164-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. FDA-2022-N-2657]

#### Agency Information Collection Activities; Proposed Collection; Comment Request; Food and Drug Administration's Study of Assessing Physiological, Neural and Self-Reported Response to Tobacco Education Messages

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the **Federal Register** concerning each proposed collection of information and to allow 60 days for public comment in response to the notice. This notice solicits comments on FDA's investigation of how youth and young adults process tobacco education messaging and to identify effective tobacco prevention and education message strategies.

**DATES:** Either electronic or written comments on the collection of information must be submitted by January 23, 2023.

**ADDRESSES:** You may submit comments as follows. Please note that late, untimely filed comments will not be considered. The <https://www.regulations.gov> electronic filing system will accept comments until 11:59 p.m. Eastern Time at the end of January 23, 2023. Comments received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are received on or before that date.

#### Electronic Submissions

Submit electronic comments in the following way:

- **Federal eRulemaking Portal:** <https://www.regulations.gov>. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to <https://www.regulations.gov> will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or